Core Insights - WestCX has launched Rich Communication Services (RCS) and Dynamic QR capabilities to enhance patient engagement and operational efficiency in healthcare [1][2] - The solutions aim to balance clinical excellence with financial performance, providing tools for cost reduction and revenue capture while ensuring compliance [2][3] Company Overview - WestCX is part of the West Technology Group, offering AI-powered omnichannel solutions through its brands Mosaicx and TeleVox [5] - The company has over 30 years of experience in delivering enterprise customer experience solutions, focusing on digital patient relationship management and conversational AI [5] Product Features and Benefits - RCS and Dynamic QR are designed to reduce manual outreach for clinicians and improve adherence, while also providing operational leaders with better margin protection and faster ROI [2] - Early deployments have shown significant benefits, including 50-80% higher conversion rates compared to SMS/email, approximately 20% revenue uplift from reduced no-shows, and threefold engagement increases through interactive features [6] Event Participation - WestCX is demonstrating its RCS and Dynamic QR solutions at the Becker's Health IT + Digital Health + RCM Conference in Chicago from September 30 to October 3 [3] - Attendees can experience firsthand how these innovations transform clinical workflows and patient engagement [3]

Moneta Health, a brain health startup delivering AI-powered cognitive rehabilitation therapy, has secured $4.5 million in funding. The company is advised by Kent Bradley, president of 10X Health, which was co-founded by entrepreneur Grant Cardone. The startup, which announced the funding round on Sept. 23, has developed an AI-powered platform that delivers cognitive rehabilitation therapy through phone-based sessions, eliminating the need for apps or high-speed internet connections. The Las Vegas-based co ...

Core Insights - Acentra Health's Chief Health and Informatics Officer, Dr. Ryan Bosch, has been recognized as a 2025 Innovator in Health Care by the Washington Business Journal for his contributions to healthcare innovation [1][2] Company Overview - Acentra Health is a technology and health solutions company focused on improving health outcomes for clients and the populations they serve [1] - The company combines public sector knowledge, clinical expertise, and technological innovation to modernize healthcare experiences for various partners [4] Leadership and Contributions - Dr. Bosch is a practicing internal medicine physician and a U.S. Air Force veteran, known for integrating social risk data with clinical and claims information to enhance care delivery in state Medicaid programs [2] - Under Dr. Bosch's leadership, Acentra Health has improved health outcomes for vulnerable populations across 47 states [2][3] - His efforts in data modernization have enabled states to utilize predictive analysis to address health disparities and reduce program costs [3] Innovation and Impact - Dr. Bosch's work focuses on transforming complex data into actionable insights, allowing public and commercial sector partners to provide smarter, more connected care [3] - The company aims to raise the standard of care while advancing the field of population health through data-driven strategies [3]

Core Points - Veradigm LLC experienced a data breach that was discovered around July 1, 2025, involving unauthorized access to customer data [1][3] - The breach likely exposed sensitive personal information, including names, Social Security numbers, contact details, dates of birth, health records, insurance information, payment data, and driver's license numbers [4] Company Overview - Veradigm LLC is a healthcare technology company that provides data-driven tools and solutions aimed at enhancing patient care and reducing healthcare costs [2] Incident Details - The data breach occurred around December 15, 2024, shortly after another security issue affected a different client of Veradigm [3] - The compromised storage account was the entry point for the unauthorized access to customer data [3] Legal Actions - Edelson Lechtzin LLP is investigating potential class action lawsuits for individuals whose sensitive personal data may have been compromised due to the breach [5]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Good Doctor Cloud Healthcare & Technology Group Co., Ltd. 四川好醫生雲醫療科技集團股份有限公司 (A joint stock company incorporated in the People's Republic of China ...

Core Insights - Rocket Doctor AI Inc. is a healthcare technology company focused on AI-powered solutions to enhance healthcare accessibility throughout the patient journey [1][3] - The company will present at the CANTech Letter Investment Conference on October 9, 2025, highlighting its platform, recent milestones, and growth strategy [1][2][6] Company Overview - Rocket Doctor AI delivers physician-built, AI-powered solutions aimed at making high-quality healthcare accessible [3] - The company's technology includes the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from numerous physicians globally [3] Technology and Impact - The company has empowered over 300 MDs to provide care for more than 700,000 patient visits, enabling doctors to manage their own virtual or hybrid practices [4] - By reducing administrative burdens, the technology allows for more meaningful physician-patient interactions and aims to improve access to care for underserved communities in Canada and patients on Medicaid and Medicare in the U.S. [5] Conference Participation - Dr. Essam Hamza and Dr. William Cherniak will present at the conference, discussing how Rocket Doctor AI's solutions streamline workflows and improve patient outcomes [2][6]

Core Insights - The value of medical AI lies not just in technical parameters but in its integration into clinical scenarios to solve real problems, as stated by JD Health CEO Jin Enlin during the JD Global Technology Explorers Conference [2] - JD Health announced the upgrade of its medical model "Jingyi Qianxun 2.0" and the launch of "AI Hospital 1.0," highlighting the deep integration of AI with various industries and the importance of high-quality data [2][3] Company Developments - The Jingyi Qianxun model, launched in 2023 and upgraded to version 2.0 in June, is the first medical model capable of understanding medical reports and patient descriptions, aiming to approach human clinical cognition [3] - JD Health's AI Hospital 1.0, launched on September 25, features over a thousand expert doctor AI agents and provides comprehensive services from diagnosis to medication [3][4] - Since its independence from JD Group in 2019, JD Health has seen significant growth, with total revenue of 35.3 billion yuan in the first half of 2023, a 24.5% year-on-year increase, and a net profit of 3.57 billion yuan, up 35% [4] Industry Trends - The rapid deployment of large models in various vertical industries, including healthcare, is exemplified by JD's initiatives, which also extend to logistics, industrial, and e-commerce sectors [5] - Data quality is crucial for the success of large models, with JD focusing on enhancing data quality through rigorous selection processes and addressing challenges related to fragmented and high-privacy data in the B2B market [6] - The integration of AI in healthcare is part of a broader trend where industries are leveraging advanced models to improve efficiency and service delivery [5][6]

Company Overview - TruBridge, Inc. (TBRG) focuses on providing technology solutions for the U.S. healthcare sector, particularly for small rural and community hospitals [2] - The company operates in two main segments: Financial Health, which includes revenue cycle management services, and Patient Care, which encompasses electronic health records and patient engagement platforms [2] Financial Performance - Financial Health now accounts for 64% of TruBridge's revenue and is identified as the company's growth engine [3] - The company has experienced significant impairments due to costly acquisitions, impacting performance and leading to all-time low share prices in 2023 [3] - Cash flow has improved through tighter working capital management and debt reduction, with leverage decreasing from 4.4x in 2024 to a manageable range of 2.5x–3x [4] Governance and Investment - New investors, including Pinetree Capital and Ocho Investments, now hold a combined 25% stake in TruBridge, prompting governance reforms such as annual board elections and the removal of the poison pill [3] - Improved governance and stronger financial discipline are seen as catalysts for a turnaround story for TruBridge [5] Strategic Focus - TruBridge is concentrating on expanding its Financial Health services while leveraging strong retention rates in Patient Care for cross-selling opportunities [4] - The company is also pursuing offshore operations to reduce costs and improve margins, targeting a 20% adjusted EBITDA [4] Market Outlook - Regulatory risks persist, particularly regarding potential funding changes related to Medicare and Medicaid, but stricter compliance requirements may increase demand for TruBridge's solutions [5] - The combination of governance reforms, financial discipline, and a clear margin expansion strategy positions TruBridge for potential upside [5]

Core Insights - Tempus AI stock experienced a significant 161% gain since the beginning of the year, but recently faced a decline following a well-known investor's decision to reduce her position in the stock [1][2] - The stock fell 12.4% from the end of last Friday's trading to the close of Thursday's market session [2] - Ark Invest reduced its position in Tempus AI by 62,352 shares, valued at approximately $5.2 million, impacting its weighting in the ARK Innovation ETF [4] Company Developments - Tempus AI received 510(k) clearance from the U.S. FDA for its RNA-based Tempus xR IVD device, aimed at supporting drug development programs [5] - Despite the reduction in the ARK Innovation ETF, Tempus AI remains the largest position in the ARK Genomic Revolution ETF, with a 10.7% weighting [5][6] Investor Sentiment - The reduction by Ark Invest may cause concern among investors, but the stock's significant position in the ARK Genomic Revolution ETF indicates continued support [6] - Ark Invest's trading strategy often involves buying and selling stocks, suggesting potential future purchases of Tempus AI if the stock price declines further [7]

BROSSARD, Quebec, Sept. 25, 2025 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using Artificial Intelligence (AI) technologies, announces the voting results of the annual meeting of the shareholders held earlier today. Mr. André Larente, Mr. Robert Dunn, Mr. Michael Braeuel and Mr. Philippe Couillard were elected as directors to hold office until the closing of the next annual meeting of t ...